Newell
Impact in
-
- Cancer survivorship and care
- Colorectal Cancer Treatments and Studies
Papers in
- Oncology 8
- Colorectal Cancer Treatments and Studies 4
- Cancer Treatment and Pharmacology 4
- PARP inhibition in cancer therapy 2
-
- Cancer therapeutics and mechanisms 2
- Co-authors
- Rob Sanson‐Fisher (2 shared papers)Stephen P. Ackland (1 shared paper)KR Harrap (5 shared papers)A H Calvert (5 shared papers)AH Calvert (4 shared papers)Michael Jarman (1 shared paper)A.L. Jackman (3 shared papers)Ewa Sikora (2 shared papers)
- Journals
- Clinical Cancer Research (3 papers)British Journal of Cancer (2 papers)Veterinary Ophthalmology (2 papers)Cellular & Molecular Biology Letters (1 paper)Anticancer Research (1 paper)
- Partner nations
- United KingdomAustraliaUnited States
In The Last Decade
Newell
20 papers receiving 241 citations
Peers
Comparison fields: 5 of 95
- Oncology 132
- Equine 4
- Pediatrics, Perinatology and Child Health 45
- Public Health, Environmental and Occupational Health 65
- Ophthalmology 20
Countries citing papers authored by Newell
This map shows the geographic impact of Newell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Newell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Newell more than expected).
Fields of papers citing papers by Newell
This network shows the impact of papers produced by Newell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Newell. The network helps show where Newell may publish in the future.
Co-authors
The 25 scholars most cited alongside Newell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1999 | 83 | |
| 2 | 2000 | 33 | |
| 3 | Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717). | 1987 | 25 |
| 4 | Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. | 1986 | 22 |
| 5 | 1999 | 21 | |
| 6 | 1999 | 20 | |
| 7 | 2018 | 17 | |
| 8 | Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion | 1995 | 10 |
| 9 | Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide | 2005 | 6 |
| 10 | Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) | 1987 | 5 |
| 11 | Persuasion In Marketing: The Dynamics Of Marketing's Great Untapped Resource | 1981 | 4 |
| 12 | 1968 | 3 | |
| 13 | DIPYRIDAMOLE INDUCED-INHIBITION OF THYMIDINE INCORPORATION INVIVO AND POTENTIATION OF CB3717 CYTO-TOXICITY INVITRO | 1985 | 2 |
| 14 | Validation of pharmacologically-guided dosing of carboplatin in paediatric patients | 1998 | 2 |
| 15 | HIV Incidence Estimation Using the BED Capture Enzyme Immunoassay : Systematic Review and Sensitivity Analysis. | 2010 | 2 |
| 16 | The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in pediatric patients: A review. | 1994 | 2 |
| 17 | The Evaluation of Homer as a Marine Corps Expeditionary Energy Pre-Deployment Tool | 2014 | 2 |
| 18 | PHARMACOKINETIC STUDIES IN HUMANS WITH CB3717 (N-(4-(2-AMINO-4-HYDROXY-6-QUINAZOLINYL)METHYL)PROP-2-YNYLAMINO)BENZOYL)-L-GLUTAMIC ACID) | 1983 | 1 |
| 19 | BIOCHEMICAL DISTURBANCES OBSERVED INVITRO AND INVIVO FOLLOWING INHIBITION OF THYMIDYLATE SYNTHETASE BY C-3717 | 1982 | 1 |
| 20 | Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase | 2000 | 1 |
About Newell
Newell is a scholar working on Oncology, Molecular Biology, Organic Chemistry, Dermatology and Pediatrics, Perinatology and Child Health, having authored 21 papers that have together received 263 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (4 papers), Quinazolinone synthesis and applications (2 papers), Glaucoma and retinal disorders (2 papers), Cancer therapeutics and mechanisms (2 papers), Chemotherapy-related skin toxicity (2 papers), PARP inhibition in cancer therapy (2 papers) and Corneal surgery and disorders (2 papers). The work is most often cited by research in Oncology (132 citations), Equine (4 citations), Pediatrics, Perinatology and Child Health (45 citations), Public Health, Environmental and Occupational Health (65 citations) and Ophthalmology (20 citations). Newell has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include Rob Sanson‐Fisher, Stephen P. Ackland, KR Harrap, A H Calvert, AH Calvert, Michael Jarman, A.L. Jackman, Ewa Sikora, S. J. Harland and Barbara Grzelakowska-Sztabert. Their work appears in journals such as Clinical Cancer Research, British Journal of Cancer, Veterinary Ophthalmology, Cellular & Molecular Biology Letters and Anticancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.